Mitem Pharma

Executive Summary

Mitem Pharma is a French biotechnology company founded in 2018 and headquartered in Paris, focusing on small molecule therapeutics that target mitochondrial dysfunction. The company addresses mitochondrial impairments, which are implicated in a range of metabolic and neurodegenerative diseases such as mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and Parkinson's disease. By harnessing novel mechanisms to restore mitochondrial function, Mitem aims to provide disease-modifying treatments where few options exist. Although initially classified under generic drugs, the company's current pipeline emphasizes innovative, first-in-class approaches, positioning it as an emerging player in the precision therapeutics space. The company remains privately held with limited public disclosure on funding and valuation, indicating an early-stage profile.

Upcoming Catalysts (preview)

• Q1 2027Initiation of first-in-human Phase I trial for lead candidate65% success
• Q4 2026Announcement of Series A funding round70% success
• Q2 2026Publication of preclinical efficacy data in peer-reviewed journal80% success